id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-273149-b1qsnxr1	Ramjug, Sheila	ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly	2020-10-13		.txt	text/plain	5562	287	45	The use of risk stratification in relation to pulmonary arterial hypertension (PAH) was heavily featured and the scientific sessions informing the respiratory community of potential biomarkers and targets for future therapies were thought-provoking. It is also important to consider risk factors for possible chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease in both the symptomatic and asymptomatic patient, which are helpfully listed in the new guidance [17] [18] [19] . [24] also demonstrated that ILD-related PH patients, at right heart catheterisation, had lower mPAP and PVR when compared to their idiopathic pulmonary arterial hypertension (PAH) cohort; despite these findings, mortality was high in both groups. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)	./cache/cord-273149-b1qsnxr1.txt	./txt/cord-273149-b1qsnxr1.txt